Breast Implant-Associated Lymphoma
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The Law Offices of Thomas J. Lamb represents people who have been harmed by unsafe medical products, including cases involving breast implant-associated lymphoma.
In more detail, the US Food and Drug Administration (FDA) has received reports about women who have had breast implant procedures done and, later, were diagnosed with these medical conditions:
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
- Anaplastic Large Cell Lymphoma (ALCL)
- Breast Implant-Associated Lymphoma
We encourage you to submit a Breast Implants Cancer Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible breast implant-associated lymphoma case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.
We are here to help the women and families who have experienced this unfortunate situation. We have successfully handled personal injury and wrongful death cases for people throughout the country.
Our firm does not put its clients into large class action lawsuits. Rather, an individual lawsuit is filed for each case. There are no costs associated with having us review your possible breast implant-associated lymphoma case.
Be assured that the information you provide to our law firm is treated as strictly confidential. Submitting a case evaluation does not obligate you to hire our law firm.
Lastly, we want you to know that you will get a reply directly from attorney Tom Lamb no later than the next business day.
Most Recent Article on This Topic
From this recent FDA Safety Communication “UPDATE: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants” we get the following information about the new reporting system for cases of breast implant-associated lymphoma — the shorthand term for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL):
As of March 22, 2023, health care providers can submit case reports of SCC, various lymphomas, and any other cancers in the capsule around breast implants to the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (ALCL) Etiology and Epidemiology (PROFILE) Registry, a collaborative effort between the American Society of Plastic Surgeons (ASPS), the Plastic Surgery Foundation (PSF), and FDA. Health care providers can continue to submit case reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) to PROFILE as well.
Next, we turn to this March 6, 2023, MedPage Today news report, “Cases of Breast Implant-Associated Lymphoma Continue to Accumulate”, which provided updates on the number of breast implant-associated lymphoma deaths and diagnoses in the US and worldwide.
As of late 2022, the American Society of Plastic Surgeons global tracking network had accumulated 1,333 cases of BIA-ALCL worldwide and 35 associated deaths. The total included 402 cases and eight deaths in the U.S. The FDA has received information on 59 deaths, said Kelly K. Hunt, MD, of the University of Texas MD Anderson Cancer Center in Houston, during the Miami Breast Cancer Conference.
We continue to handle cases of breast implant-associated lymphoma, and we offer a Free Case Evaluation for women diagnosed with BIA-ALCL.[Read article in full at original source]
Our earlier articles about this breast implants lymphoma cancer situation:
- Breast Implants Lymphoma Cancer ALCL Case Numbers Increasing Rapidly in the US
- Health Canada Breast Implant Safety Review Shows High Risk of BIA-ALCL with Textured Implants
- FDA Sets New Regulations for Breast Implant Manufacturers
- BIA-ALCL Current Recommendations and Potential Future FDA Guidance Changes
- BIA-ALCL Case Studies Confirm Importance of Proper Treatment
- Black Box Warning Label Change for Breast Implants Finalized by the FDA
- New BIA-ALCL Cases Identified in Updated FDA Report
- Most American Women Are Unaware of BIA-ALCL
- Allergan Aesthetics Launches Tracking Campaign for U.S. Breast Implant Patients
- Advances Made in Understanding and Treatment of BIA-ALCL
- Cancer Linked to Breast Implants: Is it Considered Rare Anymore?
- FDA Proposes New Recommendations for Breast Implant Labels
- TGA Regulations on Breast Implant Products
- FDA Recalls Allergan Textured Implants
- Statistics Show An Increased Risk For BIA-ALCL With Textured Implants
- Textured Breast Implants Ban: Onto Australia
- FDA Fails When It Comes To Banning Textured Breast Implants
- Textured Breast Implants Bans on the Rise
- March 2019 FDA Meeting On Breast Implants: A Summary Of What You Need To Know
- Breast Implants FDA March 2019 Meeting: Lymphoma Cancer Was A Main Topic
- 2019 Discoveries and Warnings on Breast Implant-Associated Lymphoma
- Breast Implants Lymphoma Cancer Cases Update February 2019 – US & Canada
- Allergan Textured Breast Implants Recalled In Europe Due To BIA-ALCL
- FDA Provides Updated Number of Breast Implants Lymphoma Cancers
- New Data Released on Risk of Lymphoma Due to Breast Implants
- Breast Implant-Associated Lymphoma Diagnoses on the Rise
- What is the Risk of Death Due to Breast Implant-Associated Lymphoma?
- Treatments For Breast Implants Associated Lymphoma And Blood Cancer
- Breast Implants and Lymphoma: Who’s to Blame?
- Breast Implants Lymphoma Cancer: Diagnosis And Treatment Developments
- Breast Implant Lymphoma: Causes Uncertain, but Costs Undeniable
- March 2017 FDA Report: Breast Implants Linked To Lymphoma Blood Cancer
- Breast Implants Linked to Rare Lymphoma Blood Cancer
- Summary of Information
- The Disease
- FDA Information
- Frequently Asked Questions
➤ About the Disease
➤ Risk Factors